#United States #San Jose #Genomics #Complete Genomics #NGS solutions

Complete Genomics Expands Manufacturing in the U.S.

In a strategic move for enhanced genomic solutions, Complete Genomics, a leader in genomic sequencing technologies, has significantly expanded its U.S. manufacturing and technological capabilities. This move is aimed at creating a more reliable and diversified supply chain for its next-generation sequencing (NGS) products, especially after the disruptions caused by geopolitical issues and other challenges faced in 2023.

Establishing a Localized Supply Chain

In response to the previous year’s hurdles, Complete Genomics undertook a pivotal localization strategy in 2024. This included the inauguration of two major facilities in the U.S. to solidify its manufacturing base. A highlight of this expansion is the establishment of a new 10,115 square foot manufacturing site at the company's headquarters in San Jose, California. This facility is designed to optimize delivery times and ensure reliable supply for customers across North America.

The San Jose site is now operational and focuses mainly on the production of DNBSEQ-G99RS* sequencers, reasonably priced instruments designed for small genome and targeted gene research. These sequencers are known for their remarkable efficiency, providing results in a mere 12 hours with preliminary reports available within 2.5 hours.

Focusing on Quality and Compliance

To bolster its reputation for quality, Complete Genomics has enhanced its quality assurance measures and training programs. The company attained its first Nationally Recognized Testing Laboratory (NRTL) certification for G99 production in North America, marking a significant achievement in regulatory compliance. Moving forward, Complete Genomics plans to expand its reagent production capabilities for both G99 and DNBSEQ-T7RS™ products and aims to achieve ISO 13485 certification, which represents a commitment to stringent quality management systems in manufacturing.

Rob Tarbox, the company's VP of Product and Marketing, stated that the blueprint used for G99 manufacturing will be replicated for the T7 products, reinforcing Complete Genomics' strategy to have robust local manufacturing in the United States.

Customer Engagement and Experience

Alongside the West Coast expansion, there is a new Customer Experience Center (CEC) located in Framingham, Massachusetts. This facility opened in May 2024 and serves as an interactive lab for customers to explore Complete Genomics’ extensive DNBSEQ™ workflows, enhancing offers from sample preparation automation to bioinformatics solutions.

Strategic Partnerships Fueling Growth

In the past year, Complete Genomics entered into several strategic partnerships to boost its offerings. Notable collaborations include:

• - NVIDIA: Integrated NVIDIA Parabricks into its services, thus providing researchers with quicker and more accurate genomic analysis.
• - seqWell: Enhanced library preparation products which are now fully compatible with Complete Genomics' NGS systems.
• - AdvancedDx Biological Laboratories: Merging their proprietary DeepChek® assays with Complete Genomics’ platforms across microbiological labs.
• - Eurofins Clinical Enterprise: Joining its Sequencing Service Provider Program to extend access to top-quality sequencing services.

These partnerships signify Complete Genomics' commitment to innovation and comprehensive service delivery in the genomics landscape.

Product Innovations and Market Expansion

The innovative team continued to enhance the product lineup with advancements in multi-omics and spatial transcriptomics, showcased at major gatherings such as the American Society of Human Genetics (ASHG) meeting. Noteworthy developments included the launch of the Spatial Xcellerator Grant Program to advance spatial omics research. Their innovation pipeline responded to pressing needs, exemplified by a new mpox virus amplicon sequencing panel aimed at enhancing infectious disease study tools.

Looking Ahead: A Vision of Growth

Reflecting on this transformative year, Dr. Radoje Drmanac, the Founder and Chief Scientific Officer of Complete Genomics, noted how these expansions in manufacturing, customer support, strategic collaborations, and innovative product development set the stage for ongoing growth in the genomic technology field. The company remains dedicated to advancing cost-effective and high-throughput sequencing technologies to facilitate groundbreaking research and clinical applications.

Professional stakeholders and enthusiasts in genomics are eager to see how these exciting advancements will shape the future of research and healthcare.